000178190 001__ 178190
000178190 005__ 20240229133801.0
000178190 0247_ $$2doi$$a10.1016/j.ajog.2021.12.022
000178190 0247_ $$2pmid$$apmid:34921803
000178190 0247_ $$2ISSN$$a0002-9378
000178190 0247_ $$2ISSN$$a1085-8709
000178190 0247_ $$2ISSN$$a1097-6868
000178190 0247_ $$2altmetric$$aaltmetric:119469922
000178190 037__ $$aDKFZ-2021-03188
000178190 041__ $$aEnglish
000178190 082__ $$a610
000178190 1001_ $$0P:(DE-HGF)0$$aBurchardt, Norah A$$b0$$eFirst author
000178190 245__ $$aOral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
000178190 260__ $$aSt. Louis, Mo.$$bMosby$$c2022
000178190 3367_ $$2DRIVER$$aarticle
000178190 3367_ $$2DataCite$$aOutput Types/Journal article
000178190 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655286454_9351
000178190 3367_ $$2BibTeX$$aARTICLE
000178190 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178190 3367_ $$00$$2EndNote$$aJournal Article
000178190 500__ $$a#EA:C020#LA:C020# / 2022 Jun;226(6):821.e1-821.e26
000178190 520__ $$aOral contraceptive (OC) use has been associated with higher breast cancer risk; however, evidence on the associations between different OC formulations and breast cancer risk, especially by disease subtype, is limited.To evaluate associations between OC use by formulation and breast cancer risk by disease subtype.This prospective cohort study included 107,069 women from the Nurses' Health Study II with recalled OC use from age 13 to baseline (1989) and updated data on OC use until 2009 collected via biennial questionnaires. A total of 5,799 breast cancer cases were identified through 2017. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals [95% CI] for associations between OC use and breast cancer risk, overall and by estrogen and progesterone receptor and HER2 status. OC use was evaluated by status of use (current, former, and never), duration of and time since last use independently and cross-classified, and formulation (i.e., estrogen and progestin type).Current OC use was associated with higher risk of invasive breast cancer (HR 1.31 (95% CI 1.09-1.58), vs. never use), with stronger associations with longer duration of current use (>5 years, 1.56 (1.23-1.99); ≤5 years, 1.19 (0.95-1.49)). From >5 years since cessation, risk among former and never users was similar (e.g., >5-10 years since cessation, 0.99 (0.88-1.11)). Associations did not differ significantly by tumor subtype. In analyses by formulation, current use of formulations containing levonorgestrel in triphasic (2.83 (1.98-4.03)) and extended cycle regimens (3.49 (1.28-9.53)), and norgestrel in monophasic regimen (1.91 (1.19-3.06); vs. never OC users), all combined with ethinyl estradiol, was associated with higher breast cancer risk. No association was observed with current use of the other progestin types evaluated (norethindrone, norethindrone acetate, ethynodiol diacetate, desogestrel, norgestimate, and drospirenone), though sample sizes were relatively small for some of the subgroups, limiting these analyses.Current OC use was associated with higher risk of invasive breast cancer regardless of disease subtype, though risk was comparable to never users 5 years after cessation. In analyses by progestin type, associations were observed for select formulations including levonorgestrel and norgestrel. Assessment of the associations for newer progestin types (desogestrel, norgestimate, drospirenone) was limited by sample size, and further research on more recently introduced progestins is warranted.
000178190 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178190 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178190 650_7 $$2Other$$abreast cancer
000178190 650_7 $$2Other$$aepidemiology
000178190 650_7 $$2Other$$aestrogen
000178190 650_7 $$2Other$$ahormonal contraception
000178190 650_7 $$2Other$$amolecular subtypes
000178190 650_7 $$2Other$$aoral contraception
000178190 650_7 $$2Other$$aprogestin
000178190 650_7 $$2Other$$arisk factors
000178190 7001_ $$aEliassen, A Heather$$b1
000178190 7001_ $$aShafrir, Amy L$$b2
000178190 7001_ $$aRosner, Bernard$$b3
000178190 7001_ $$aTamimi, Rulla$$b4
000178190 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b5$$udkfz
000178190 7001_ $$aTworoger, Shelley S$$b6
000178190 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b7$$eLast author$$udkfz
000178190 773__ $$0PERI:(DE-600)2003357-6$$a10.1016/j.ajog.2021.12.022$$gp. S0002937821026867$$n6$$p821.e1-821.e26$$tAmerican journal of obstetrics and gynecology$$v226$$x0002-9378$$y2022
000178190 909CO $$ooai:inrepo02.dkfz.de:178190$$pVDB
000178190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000178190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000178190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000178190 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178190 9141_ $$y2021
000178190 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000178190 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000178190 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000178190 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J OBSTET GYNECOL : 2021$$d2022-11-25
000178190 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bAM J OBSTET GYNECOL : 2021$$d2022-11-25
000178190 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000178190 980__ $$ajournal
000178190 980__ $$aVDB
000178190 980__ $$aI:(DE-He78)C020-20160331
000178190 980__ $$aUNRESTRICTED